Early diagnosis, appropriate treatment and adherence to treatment, key to the prevention of the refractory arterial pressure.

– refractory arterial pressure is defined as one that persists over nive – them acceptable despite treatment with three or more medications

-experts agree that combinations to fixed-dose antihypertensives drugs obtained best results with hypertension at simplify treatment and favore-cer treatment adherence

Madrid, March 2012.- in recent times, one of the aspects that concern most specialists in high blood pressure (hypertension) is the approach of the refractory or resistant, ETS which is defined as one that does not descend to acceptable levels of pressure (below 140/90 mmHg) despite treatment with full doses of three or more drugs antihypertensives belonging to different families or groups of antihypertensive. This has been the subject of the plenary meeting is possible to prevent the refractory hypertension?, organized within the seventeenth meeting of the Spanish society of hypertension – Spanish League for the fight against Arterial hypertension (SEH-LELHA), which was held in Madrid from 7 to 9 March.

Refractory arterial pressure could be prevented if several conditions are met: the first that the diagnosis early, when there is no important effects on target organs; the second to introduce the appropriate treatment for hypertension and other risk factors, and the third the patient adequately take the medication and follow the rules of life and diet that your doctor will prescribe , explains the DRA. Nieves Martell, section head of the unit of Arterial hypertension of the Hospital Clínico San Carlos de Madrid and President of the SEH-LELHA

Importance of the combinations

Improve blood pressure in the refractory patient goes inevitably to improve adherence you-rapéutico. Is the most important barrier that we find ourselves in hypertension, because non-compliance leads to lack of control and, therefore, an increase in cardiovascular risk , says Dr. Josep Redón, Chief of service of internal medicine and coordinator of the unit of hypertension of the Hospital Clínico Universitario of Valencia and current President of the society European of hypertension)(ESH by its English acronym).

The refractory patient is usually treated with two, three and sometimes four or more drugs. Studies have shown that, as it increases the number of pills, the patient compliance decreases. This situation they take special importance combinations to fixed doses of drugs, which simplify the treatment and promote compliance with, and as such, they are recommended by the guides of the European society of hypertension and the European society of cardiology. As it increases the number-mere of drugs to take, there are more possibilities for the patient to forget any of them, resulting in inadequate coverage and blood pressure is not well controlled. Therefore, if the patient can take 2 or 3 pills in a single, the chances of failure are minimized significantly ”, summarizes the DRA. Martell. The same opinion is Dr. Redón, who says: the use of combinations simplifies treatment and improves compliance. The taking of a single compressed journal facilitates the patient complies with his medication and that control can be achieved in larger proportion ”.

Integral approximation

HypertensionCare, the integrated solution developed by the company Daiichi Sankyo that provides health professionals with a wide range of products, services and knowledge, includes various combinations to fixed-dose Sevikar ® (olmesartan and maleate), Sevikar HCT ® (amlo-dipino, olmesartan and hydrochlorothiazide) and Olmetec Plus ® (olmesartan and hydrochlorothiazide) which allow doctors to adapt to each type of hypertensive patient treatment needs. The comprehensive approach to the management of hypertension is the only way we have to reduce the possibility of the patient suffers a cardiovascular accident. Therefore, all initiatives that help achieve these propósi-cough are laudable and help both the patient and the doctor to achieve the objectives ”, concludes regard-to the DRA. Martell.

Daiichi Sankyo is the seventeenth annual meeting of SEH-LEHLA Gold partner. The company stands out for its continuous commitment to the development of therapeutic solutions to hypertension and this is the fifth consecutive year that collaborates with SEH-LEHLA for implementation underway at the main meeting on hypertension which takes place in Spain.

ETS: first cause of mortality worldwide

In Spain there are more than 10 million hypertensive, representing 35 percent of the adult population suffers from this condition, a figure that it rises to more than 60% in those over 60 years. These data have become to high blood pressure one of the major health problems, because while it is a silent disease that shows no apparent signs, it is one of the major cardiovascular risk factors. In fact, the World Health Organization (who) shares this vision and puts the hypertension as the first cause of mortality worldwide because it is the cause of 49 per cent of the cases of coronary heart disease and the 62 per cent of the stroke and other cerebrovascular accidents.

About Daiichi Sankyo

The Daiichi Sankyo group is dedicated to the research and supply of pharmaceutical products innova Рobservers, both in mature and emerging markets, facing various medical needs of patients who are not yet covered. The company was created in 2005 through the merger of two Japanese companies of long tradition and Daiichi Sankyo. Daiichi Sankyo is one of 20 major pharmaceutical companies in the world. In parallel with the maintenance of their drugs for the hiperten-Zion, Hyperlipidemia and bacterial infections, the group is focused on the development of trafficking-Qu̩bec for disorders thrombotic, research in Oncology as well as new therapies in the cardiovascular area and metabolism. On the other hand, the Daiichi Sankyo group has created a hybrid business model , which responds to the diversity of the market and customer seeking to optimize the opportunities for growth throughout the value chain.

The company’s global headquarters is in Tokyo. Its European base, Daiichi Sankyo Europe, is in Munich and has subsidiaries in 12 European countries and a global manufacturing in Pfaffenhofen (Germany) plant.